Zostavax Vaccine 0.65 ml

Zostavax Vaccine 0.65 ml belongs to the class of medications called ‘immunizing agents’ used to prevent herpes zoster (shingles) infection. Herpes zoster is a viral infection that causes a painful rash. The varicella-zoster virus causes it. Zostavax Vaccine 0.65 ml does not cure herpes but does not allow the disease to spread and treat its symptoms.

Zostavax Vaccine 0.65 ml is an immunizing agent or vaccine made from a live, attenuated herpes-zoster virus. It helps to provide persistent or long-lasting protection against the zoster virus. Zostavax Vaccine 0.65 ml helps develop immunity by forming antibodies and stimulating the immune system. It is essential to take the vaccine doses per the doctor’s advice for effective protection against the disease.

A healthcare professional will administer Zostavax Vaccine 0.65 ml; hence, do not self-administer. Zostavax Vaccine 0.65 ml may cause side effects such as fever, headache, itching, pain, swelling, and redness at the injection site. These side effects are mild and temporary. However, if these side effects persist or worsen, inform your doctor immediately.

It is not recommended to take Zostavax Vaccine 0.65 ml if you are allergic to gelatin, neomycin or any contents present in this medicine. Zostavax Vaccine 0.65 ml should not be given for the treatment of postherpetic neuralgia, or chickenpox in people with with a weak immune system, such as patients with HIV or AIDS, who are receiving immunosuppressants or, who have active untreated tuberculosis, and who have a high temperature. Zostavax Vaccine 0.65 ml should not be given to pregnant women and used with caution in breastfeeding mothers. 

Zostavax Vaccine 0.65 ml is given by a trained healthcare professional, so do not self-administer. It is given into the muscle. If given into the muscle, the upper arm area is preferred.

Zostavax Vaccine 0.65 ml provides active immunization against herpes-zoster virus for healthy adults above 50 years of age. It benefits people who are non-immune and at risk of infection, such as healthcare workers or workers in children's daycare centres, and non-immune household contacts of patients with weak immune systems with no history of the disease. It helps protect against the zoster virus and develop immunity by forming antibodies and stimulating the immune system.

It is not recommended to take Zostavax Vaccine 0.65 ml if you are allergic to gelatin, neomycin or any contents present in this medicine. People who have been vaccinated with Zostavax Vaccine 0.65 ml should avoid close contact for up to 6 weeks with the following individuals: those who have not been previously vaccinated against chickenpox, who have a weak immune system or who are receiving immune suppressants. Adults with weak immune systems who receive Zostavax Vaccine 0.65 ml should be closely monitored as this vaccine is less effective in these people. People should not receive any immunoglobulin medicines for one month following Zostavax Vaccine 0.65 ml. Women of childbearing potential should use reliable contraceptive methods as it is not recommended to get pregnant for three months following the Zostavax Vaccine 0.65 ml vaccination. Zostavax Vaccine 0.65 ml should not be given for the treatment of postherpetic neuralgia, or chickenpox in people with a weak immune system, such as patients with HIV or AIDS, who are receiving immunosuppressants or, who have active untreated tuberculosis, and who have a high temperature.